| Q24311894 | Asp650 is crucial for catalytic activity of neutral endopeptidase 24-11 |
| Q30714356 | Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor. |
| Q48353757 | Enkephalins. A new approach to pain relief? |
| Q33747010 | Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore |
| Q67919762 | Exploration of the catalytic site of endopeptidase 24.11 by site-directed mutagenesis. Histidine residues 583 and 587 are essential for catalysis |
| Q41669037 | Identification of glutamic acid 646 as a zinc-coordinating residue in endopeptidase-24.11 |
| Q37998313 | Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain |
| Q40811955 | Inhibitors of enkephalin-degrading enzymes as potential therapeutic agents. |
| Q73501315 | N-formyl hydroxylamine containing dipeptides: generation of a new class of vasopeptidase inhibitors |
| Q74578234 | New orally active enkephalinase inhibitors: their synthesis, biological activity, and analgesic properties |
| Q43719535 | Opioid and GABA receptors involved in mediation and modulation of tonic and stimulus-evoked inhibition of a spinal reflex in the decerebrated and spinalized rabbit |
| Q34334996 | Substitution of potential metal-coordinating amino acid residues in the zinc-binding site of endopeptidase-24.11. |
| Q39856924 | The Analgesic Activity of Bestatin as a Potent APN Inhibitor |
| Q44352373 | The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced spinal c-Fos expression are completely blocked by beta-funaltrexamine, a selective mu-opioid receptor antagonist |